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Abstract
Background: Sera from convalescent Lassa fever patients often contains antibodies to Lassa virus (LASV) glycoprotein
1 (GP1), and glycoprotein 2 (GP2); Immunization of non-human primates with viral vectors expressing the arenaviral
glycoprotein complex (GPC) confers full protective immunity against a lethal challenge with LASV. Thus, the
development of native or quasi native recombinant LASV GP1 and GP2 as soluble, uncoupled proteins will improve
current diagnostics, treatment, and prevention of Lassa fever. To this end, mammalian expression systems were
engineered for production and purification of secreted forms of soluble LASV GP1 and GP2 proteins.
Results: Determinants for mammalian cell expression of secreted uncoupled Lassa virus (LASV) glycoprotein 1 (GP1)
and glycoprotein 2 (GP2) were established. Soluble GP1 was generated using either the native glycoprotein precursor
(GPC) signal peptide (SP) or human IgG signal sequences (s.s.). GP2 was secreted from cells only when (1) the
transmembrane (TM) domain was deleted, the intracellular domain (IC) was fused to the ectodomain, and the gene was
co-expressed with a complete GP1 gene in cis; (2) the TM and IC domains were deleted and GP1 was co-expressed in
cis; (3) expression of GP1 was driven by the native GPC SP. These data implicate GP1 as a chaperone for processing and
shuttling GP2 to the cell surface. The soluble forms of GP1 and GP2 generated through these studies were secreted as
homogeneously glycosylated proteins that contained high mannose glycans. Furthermore, observation of GP1
ectodomain shedding from cells expressing wild type LASV GPC represents a novel aspect of arenaviral glycoprotein
expression.
Conclusion: These results implicate GP1 as a chaperone for the correct processing and shuttling of GP2 to the cell
surface, and suggest that native GPC SP plays a role in this process. In the absence of GP1 and GPC SP the GP2 protein
may be processed by an alternate pathway that produces heterogeneously glycosylated protein, or the polypeptide may
not fully mature in the secretory cascade in mammalian cells. The expression constructs developed in these studies
resulted in the generation and purification of soluble, uncoupled GP1 and GP2 proteins from mammalian cells with quasi-
native properties. The observation of GP1 ectodomain shedding from cells expressing wild type LASV GPC establishes
new correlates of disease progression and highlights potential opportunities for development of diagnostics targeting the
early stages of Lassa fever.
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Background
LASV, a member of the Arenaviridae  family, causes a
severe, often fatal, hemorrhagic fever that is endemic to
West Africa; where as many as 300,000–500,000 infec-
tions occur per year [1-3]. The case fatality rate for hospi-
talized Lassa fever patients is 15%–20%, and during
epidemics, the rate can reach as high as 50% [4,5]. The
virus is maintained in nature by its peridomestic rodent
host, Mastomys natalensis, and is primarily transmitted to
humans by aerosolized urine of infected animals, though
severe nosocomial outbreaks and imported cases of Lassa
fever in non-endemic areas have been documented [5,6].
Presently, there is no licensed vaccine or anti-viral therapy
available for the prevention or treatment of this disease,
and there is no commercially available Lassa fever diag-
nostic assay. The threat posed by LASV is heightened fur-
ther by the potential use of the virus as a biological
weapon, which is substantiated by the stability of the vir-
ion, demonstrated person-to-person transmission, the
severity of disease, lack of therapeutic and prophylactic
reagents, and the capacity for aerosolization. As a result,
LASV is classified as a Category A Priority Pathogen and
biosafety level (BSL)-4 agent by the Centers for Disease
Control and Prevention. Collectively, these factors under-
score the need for effective diagnostics, vaccines, and ther-
apies against Lassa fever. In this regard, production and
characterization of native or quasi-native recombinant
LASV glycoproteins would facilitate efforts to generate
effective countermeasures.
The LASV genome is comprised of two ambisense, single-
stranded RNA molecules, designated large (L) and small
(S), which are contained in a nucleoprotein capsid
encompassed by an outer envelope displaying surface
glycoprotein spikes [7]. The L segment encodes the viral
polymerase (L protein) and RING finger Z matrix protein;
whereas, the S segment encodes the glycoprotein precur-
sor (GPC), which is 76-kDa in length, and a 63-kDa
nucleoprotein (NP). Cleavage of GPC by the protease SKI-
1/S1P at the recognition motif RRLL results in the N-ter-
minal 42-kDa glycoprotein 1 (GP1) subunit and the C-
terminal 38-kDa glycoprotein 2 (GP2) subunit containing
a transmembrane (TM) and intracellular (IC) domain [8].
GP1 mediates virus binding to the cellular glycoprotein
receptor alpha-dystroglycan while the structure of GP2 is
consistent with viral TM fusion proteins [9,10]. GPC con-
tains a 58 residue hydrophobic N-terminal signal peptide
(SP), which directs the precursor to the endoplasmic retic-
ulum (ER) for further processing [11]. The SP, which has
been implicated in membrane fusion, may also serve a
role in proteolytic processing of the glycoprotein and, as
suggested for Junin virus (JUNV), assembly of the glyco-
protein complex [12,13].
Understanding the elaborate and complex interactions
between the SP, SKI-1/S1P proteolytic pathway, and the
glycoprotein complex would facilitate the generation of
prophylactic and therapeutic strategies. To this end, an
array of plasmids was engineered that permitted optimal
mammalian-based expression of the LASV glycoproteins,
including GPC, GP1, and GP2. Various signal peptides,
purification tags, and modifications to internal domains
were employed for the generation and characterization of
soluble, uncoupled, full-length, quasi-native LASV GP1
and GP2. Parameters required for efficient expression
were determined, affording valuable insight into LASV
glycoprotein processing and identifying glycoprotein var-
iants that may have significant implications in the patho-
genesis of LASV in humans.
Results
Expression and purification of soluble LASV GP1
Constructs expressing the native GPC SP through the C-
terminal end of mature GP1 or the same configuration
fused at the C-terminus to the TM domain of mature GP2
were engineered for production of soluble GP1 (sGP1) or
membrane-anchored GP1 (GP1-TM), respectively (Figure
1B iii and vii). Expression was achieved at high levels in
HEK-293T/17 cells using the cytomegalovirus (CMV)
major immediate early (MIE) promoter containing the
intron-A sequence. When compared to intronless counter-
parts, the intron-A sequence greatly enhanced intracellu-
lar expression of GP1-TM and sGP1 (Figure 2, lanes 1–4).
Expression of wild type GPC was similarly enhanced by
CMV intron-A (Figure 2, lanes 7 and 8). The multiple
banding patterns observed in GPC and GP1 expression
profiles likely reflected differences in glycosylation at the
time of sample preparation. High-level expression of
sGP1 was achieved irrespective of the signal sequence
fused to the N-terminus of the gene. The native GPC SP, a
19 amino acid (a.a.) human IgG light-chain (hλLC) signal
sequence (s.s.), or a 19 a.a. human IgG heavy-chain
(hHC) s.s. all resulted in the secretion of full length and
homogeneously glycosylated sGP1 and FLAG-tagged
sGP1 (sGP1-FLAG) (data not shown). As a result of these
data, subsequent studies, including co-transfections with
GP2-expressing constructs, were performed with GPC SP-
driven sGP1 or sGP1-FLAG using the CMV MIE promoter
containing intron-A.
The predominant sGP1-FLAG species detected was a
homogeneous 42-kDa monomeric form of the protein,
which was obtained from cells transfected with vector
sGP1-FLAG (Figure 3B, lane 3). A species of ca. 85-kDa,
which was only detected by a GP1-specific monoclonal
antibody (anti-GP1 mAb 2074), corresponded to a
homodimer of sGP1-FLAG, which was not easily dis-
rupted by denaturing and reducing conditions (Figure 3B,
lane 3; Figure 4C, lanes 2–4 and lane 9). A minor trimer-
ized form of sGP1-FLAG was also detected (Figure 4C,
lanes 2–4 and lane 9).Virology Journal 2008, 5:161 http://www.virologyj.com/content/5/1/161
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Graphic representation of LASV GPC, GP1, and GP2 constructs employed in the expression of glycoproteins in mammalian  cells Figure 1
Graphic representation of LASV GPC, GP1, and GP2 constructs employed in the expression of glycoproteins 
in mammalian cells. The LASV Josiah GPC gene was the backbone for all glycoprotein expression constructs. (A. i) The 58 
amino-acid signal peptide (SP) which is post-translationally cleaved by SPase precedes the 201 amino acid GP1 ORF (59 – 259). 
The GP2 ORF spans amino acids 260 – 491. The GP2 gene contains an ectodomain of 168 amino acids, followed by a 24 amino 
acid transmembrane (TM) domain, and a 40 amino acid intracellular (IC) domain. The cleavage positions of SPase and SKI-1/S1P 
proteases are indicated by arrows. The relative position of 7 N-linked glycosylation sites in GP1 and 4 in GP2 are indicated by 
Y symbols. Constructs for expression of GPC-FLAG (A. ii), GP1 (B), GP2 and soluble GPC (C), are noted. The pcDNA3.1(+) 
plasmid background was used for expression of glycoprotein constructs (D).
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Our studies indicated that approximately 50% of the
sGP1-FLAG protein could not be captured by FLAG resin
affinity chromatography. This result was not related to
insufficient binding capacity of the resin and was evident
only when comparing data from Western blot analysis
using anti-GP1 mAb 2074 to results obtained from similar
analyses using antibody specific for FLAG (FLAG M2
mAb) (Figure 3A and 3B, lane 2). Unbound sGP1-FLAG
could not be captured by reprocessing through fresh resin
(data not shown). The FLAG tag was readily detected by
Western blot in the eluted GP1 protein fraction using both
anti-GP1 and FLAG M2 mAbs (Figure 3A and 3B, lane 3).
Collectively, these results suggested that sGP1-FLAG was
partially cleaved by SKI-1/S1P protease, as the enzyme's
recognition sequence was retained in the construct and
was directly fused to FLAG (RRLL↓DYKDDDDKG).
Expression of soluble and membrane-anchored GP2
As determined for sGP1, expression of sGP2 was signifi-
cantly higher when driven by a CMV promoter containing
intron-A (data not shown), resulting in the selection of
this promoter for all GP2 analyses. Unlike GP1, neither
native GPC SP nor light- or heavy-chain IgG s.s. elicited
effective expression, processing, and secretion of GP2
when fused to the ectodomain of the protein (Figure 4A
and 4C, lanes 2–4). Irrespective of the s.s. employed,
intracellular GP2 expression resulted in highly heteroge-
neously glycosylated species of the protein (Figure 4A,
lanes 2–4). Inclusion of the GP2 TM domain in constructs
GP2 hHC-TM and GP2-λLC-TM, as outlined in Figure 1C
x and xiii, respectively, resulted in undetectable levels of
GP2 (data not shown). Thus, expression of membrane-
anchored GP2 was not pursued in subsequent studies.
Co-expression of GP1 and GP2 in trans
HEK-293T/17 cells were co-transfected with various sGP2
constructs (Figure 1C viii, xii, xiv) and expression vector
sGP1 (Figure 1B iii) to determine the co-translational
processing and secretion efficiency of the glycoprotein
complex when expressed in trans. All GP2 constructs
exhibited similar intracellular expression patterns, includ-
ing heterogeneous glycosylation, irrespective of the pres-
ence of GP1 (Figure 4A, lanes 2–7). GP2 constructs
containing a human IgG s.s. co-transfected with construct
sGP1 consistently resulted in more homogeneously glyc-
osylated intracellular GP1 (Figure 4B, lanes 5–8). None of
the transfection formats resulted in detectable levels of
sGP2 in cell culture supernatants (Figure 4C, lanes 2–7);
whereas, expression of sGP1 was confirmed in both cell
extracts and supernatants (Figure 5B and 5D, lanes 5–8),
though diminished levels of sGP1 were detected in the
supernatant of cells co-transfected with sGP2-λLC (Figure
4D, lane 6).
Co-expression of GP1 and GP2 in cis
To identify regions of GPC required for secretion of
homogenous GP1 and GP2, several constructs were engi-
neered with or without the TM or IC domains, as depicted
Intracellular expression of LASV GP1TM, sGP1, and wild type GPC from mammalian vectors driven by CMV MIE intron-A con- taining or intronless constructs Figure 2
Intracellular expression of LASV GP1TM, sGP1, and wild type GPC from mammalian vectors driven by CMV 
MIE intron-A containing or intronless constructs. Ten micrograms of total protein from HEK-293T/17 cell extracts (C) 
transfected with each DNA construct were resolved on SDS-PAGE gels, blotted onto nitrocellulose membranes and probed 
with a mix of LASV GP1-specific mAbs and an HRP-conjugated goat α-mouse IgG antibody. Protein expression from CMV 
intron-A containing GP1-TM (lane 1) and sGP1 (lane 2) constructs were compared to intronless counterparts (lane 3, GP1-
TM; lane 4, sGP1). An empty plasmid control, pcDNA3.1(+):intA, is shown in lane 5. Wild type GPC expressed from an intron-
A containing construct (lane 7) was compared to an intronless counterpart (lane 8). Expression of GPC was detected with a 
mix of LASV GP1 and GP2-specific mAbs and an HRP-conjugated goat α-mouse IgG antibody. Protein molecular weight sizes in 
kDa are indicated to the right of the panel.
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in Figure 1. Using the FLAG M2 mAb, GP2 was not
detected in extracts prepared from cells transfected with
either GPCΔTMΔIC-FLAG or GPCΔTM-FLAG (Figure 5A,
lanes 3 and 4); however, the protein was observed in cell
culture supernatants (Figure 5B, lanes 3 and 4). Con-
versely, these constructs yielded GP1 in cell extracts (data
not shown) and supernatants (Figure 5C, lanes 3 and 4),
with detection performed using anti-GP1 mAb 2074. Fur-
thermore, cells transfected with GPCΔTMΔIC, GPCΔTM-
ΔIC-FLAG, GPCΔTM-FLAG, and sGP1-FLAG produced
significant levels of sGP1 dimers and trimers (Figure 5C,
lanes 2–4 and lane 9). Transfection with GPCΔTM-FLAG,
which contained the IC domain, generally produced more
secreted GP2 per relative unit volume, but the domain
was not required for generation of fully glycosylated and
homogeneous protein (Figure 5B, lanes 3 and 4). Results
similar to those described above were obtained when
detection was performed using a GP2-specific mAb (data
not shown).
GP2 was detected in extracts but not supernatants of cells
transfected with constructs containing only the C-termi-
nal residues that code for the SKI-1/S1P protease recogni-
tion site (Figure 5A and 5B, lanes 6 and 7). This pattern of
GP2 cellular retention was also observed with constructs
sGP2-h HC, sGP-hλLC, and sGP2-GPC SP, all of which
did not contain the GP1 ORF (Figure 4, lanes 2–4). GP2
with highly heterogeneous size distribution, indicating
different levels of glycosylation, was generated when the
IC domain was omitted in addition to deletion of most of
the GP1 open reading frame (ORF) (figure 5A, lane 6),
and as expected, sGP1 was not detected in this format
(Figure 5C, lanes 5–7). Conversely, intracellular expres-
sion primarily yielded fully glycosylated GP2 of approxi-
Purification of sGP1-FLAG, GPCΔTMΔIC-FLAG, and GPCΔTM-FLAG from transiently transfected HEK-293T/17 cell superna- tants Figure 3
Purification of sGP1-FLAG, GPCΔTMΔIC-FLAG, and GPCΔTM-FLAG from transiently transfected HEK-293T/
17 cell supernatants. Supernatants from 72-hour transient transfections were subjected to IP using an ANTI-FLAG M2 aga-
rose gel. Twenty microliters of cleared supernatant (lane 1), unbound fraction (lane 2), and eluate fraction (lanes 3) were 
resolved on 10% SDS-PAGE gels, blotted onto nitrocellulose membranes and probed with anti-FLAG M2 mAb and a goat α-
mouse IgG-HRP (panel A). The blot was stripped and reprobed with anti-GP1 mAb 2074 and the same secondary as above 
(panel B). The monomer sGP1 and sGP2 species (m) on each blot are indicated by solid arrows. The GP1+GP2 polyprotein on 
each blot (poly) are indicated by broken arrows. MagicMark XP western blot molecular weight markers (M), with sizes (kDa) 
are shown to the left of the panel. The construct designations for each transfection supernatant are indicated below the figure. 
In both panels lanes 1, 4, and 7 correspond to supernatant load; lanes 2, 5, and 8 are unbound supernatant fractions; lanes 3, 6, 
and 9 are eluate fractions.
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mately 38-kDa in size when the IC domain was present
(Figure 5A, lane 7). GPC variants from constructs lacking
the IC domain resulted in significant levels of high molec-
ular weight aggregates, particularly when GP1 was not co-
expressed (Figure 5A, lanes 3, 6 and 7). This pattern was
not observed in cells transfected with construct GPCΔTM-
FLAG, which also yielded the highest levels of secreted
GP2 (Figure 5A, lane 4), nor was it evident in cells trans-
Intracellular and secreted forms of LASV GP2 variants and co-transfections with sGP1 in HEK-293T/17 cells Figure 4
Intracellular and secreted forms of LASV GP2 variants and co-transfections with sGP1 in HEK-293T/17 cells. 
Cell extracts and supernatants from HEK-293T/17 transfected with LASV GP2 variants or from co-transfections with sGP1 
were analyzed for the expression and secretion of GP1 and GP2. Ten micrograms of transfected cell protein were resolved on 
SDS-PAGE gels, blotted onto nitrocellulose membranes and probed with anti-LASV GP2 (panel A) or GP1 mAbs (panel B). 
Similarly, twenty μL of supernatant from each transfection were resolved on SDS-PAGE gels, blotted, and probed with the 
same anti-GP2 (panel C) and anti-GP1 mAbs (panel D). Control plasmid pcDNA3.1(+):intA (lane 1) was transfected alongside 
constructs sGP2-h HC (lanes 2), sGP2-hλLC (lanes 3), and sGP2-GPC SP (lane 4). The sGP2 constructs were co-transfected in 
the same order in lanes 5, 6, and 7 with equimolar amounts sGP1 expression plasmid. A transfection with sGP1 construct is 
shown in lane 8. Molecular weight markers with sizes (kDa) are shown to the left of the panel. Panels showing expression pro-
file from cell extracts (C) and supernatants (S) are demarcated by vertical lines, along with the respective anti-LASV mAb 
probes. The co-transfection profiles with GP1 and GP2 constructs are indicated by (-) and (+) symbols at the bottom of the fig-
ure.
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fected with sGP1 (Figure 5A, lane 9). High molecular
weight aggregates were also evident in cells expressing
wild type GPC, although at lesser levels than with con-
structs GPCΔ59–249ΔTMΔIC-FLAG and GPCΔ59–249ΔTM-
FLAG (Figure 5A, lane 8).
Glycosylation of sGP1 and sGP2
To examine glycosylation patterns, sGP1 and sGP2 pro-
duced in sGP1-FLAG, GPCΔTMΔIC-FLAG, or GPCΔTM-
FLAG transfected cells were subjected to cleavage with (1)
PNGase F, an amidase that cleaves between the innermost
GlnNAc and asparagines residues of high mannose,
hybrid, and complex oligosaccharides from N-linked glyc-
oproteins [14]; or (2) Endo H, a glycosidase that cleaves
the chitobiose core of high mannose and some hybrid oli-
gosaccharides from N-linked glycoproteins [14]. Based on
protein molecular weights following cleavage with
PNGase F or Endo H, sGP1 and sGP2 were secreted as gly-
cosylated proteins, with noted reductions from 42-kDa to
23-kDa for sGP1-FLAG (Figure 6, lanes 1–3), 36-kDa to
21-kDa for GPCΔTMΔIC-FLAG (Figure 6, lanes 4–6), and
38-kDa to 24-kDa for GPCΔTM-FLAG (Figure 6, lanes 7–
9).
Expression profiles of sGP1 and sGP2 from GPC variants
Western blot analysis using the anti-FLAG M2 mAb
detected a single, homogenous 36-kDa sGP2 species in
the supernatant of cells transfected with GPCΔTMΔIC-
FLAG (Figure 3A, lane 4). Following FLAG M2 gel affinity
purification, this protein was captured by the resin, as
indicated by the lack of trace detection in the unbound
fraction (Figure 3A, lane 5). Analysis of the eluate fraction
revealed two strong protein bands, a 36-kDa sGP2 mono-
mer and a larger species ca. 72-kDa in size (Figure 3A, lane
6). Supernatant prepared from cells transfected with
GPCΔTM-FLAG revealed a 38-kDa sGP2 species (Figure
3B, lane 7), and in the eluate fraction, two strong proteins
were detected, a 38-kDa sGP2 monomer and a larger spe-
cies ca. 76-kDa in size (Figure 3B, lane 9). As GPCΔTM-
ΔIC-FLAG and GPCΔTM-FLAG constructs generate full
length GP1 and truncated sGP2 variants, the blots were
subsequently stripped and reprobed with anti-GP1 mAb
2074 to confirm the presence and expression level of GP1
in purified preparations. Western blot analyses of the
supernatant load of each GPC variant detected two bands,
a 42-kDa sGP1 monomer and a 78-kDa species (Figure
3B, lanes 4 and 7). The monomeric form of sGP1 was also
readily detected in the unbound fraction (Figure 3B, lanes
5 and 8). The eluates from both GPC variants revealed
very strong bands ca. 76-kDa and 78-kDa in size, for
GPCΔTMΔIC-FLAG and GPCΔTM-FLAG, respectively
(Figure 3B, lanes 6 and 9). These proteins co-localized on
the gel with proteins detected using anti-FLAG M2 mAb
(Figure 3A, lanes 6 and 9). Collectively, these data sug-
gested that sGP1 and sGP2 form stable, covalently-
bonded heterodimer complexes or that a significant frac-
tion of the GPCΔTMΔIC-FLAG- and GPCΔTM-FLAG-gen-
erated proteins are uncleaved intracellularly by SKI-1/S1P
protease and are thereby secreted in polyprotein form.
Anti-GP1 mAb 2074 did not detect significant monomeric
sGP1 in the eluate fractions, indicating that the protein is
associated with sGP2 (Figure 3B, lanes 6 and 9). A very
Expression and secretion of sGP2 from LASV GPC deletion  variants Figure 5
Expression and secretion of sGP2 from LASV GPC 
deletion variants. Cell extracts and supernatants from 
HEK-293T/17 transfected with LASV GPC deletion variants 
were analyzed for the expression and secretion of GP1 and 
GP2 proteins. Ten micrograms of total protein from trans-
fected cells were resolved on SDS-PAGE gels, blotted onto 
nitrocellulose membranes and probed with FLAG M2 mAb 
(A). Twenty μL of supernatant from the corresponding sam-
ples were similarly resolved, blotted, and probed with FLAG 
M2 mAb (B) or anti-LASV GP1 mAbs (C). (Lane 1) control 
plasmid pcDNA3.1(+):intA, (lane 2) GPCΔTMΔIC, (lane 3) 
GPCΔTMΔIC-FLAG, (lane 4) GPCΔTM-FLAG, (lane 5) 
GPCΔ59–249 ΔTMΔIC, (lane 6) GPCΔ59–249ΔTMΔIC-FLAG, 
(lane 7) GPCΔ59–249ΔTM-FLAG, (lane 8) GPC-FLAG, (lane 9) 
sGP1-FLAG. SeeBlue® Plus2 pre-stained molecular weight 
markers (M), with sizes (kDa) are shown to the right of the 
panel. Designations for the constructs that generated the 
intracellular expression pattern in lanes 6A and 7A are dis-
played to the left of panel A. Similarly, designations that gen-
erated the secreted expression pattern in lanes 3B and 4B 
are displayed to the left of panel B. Positions of monomer 
(m), dimer (d), and trimer (t) forms of the GP1 protein are 
indicated by arrows. Similarly, the position of monomeric (m) 
and dimerized (d) forms of sGP1 (right), and polyprotein 
(poly) species consisting of sGP1+sGP2 (left) in panel B are 
indicated by arrows.
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minor component ca. 110-kDa in size was detected in
most preparations of GPCΔTM-FLAG using anti-GP1 mAb
2074, which potentially represented additional mul-
timeric complexes (Figure 3B, lanes 7 and 9). These results
indicated that approximately 50% of the sGP2 generated
from GPCΔTMΔIC-FLAG and GPCΔTM-FLAG is associ-
ated with sGP1, whereas ~50% is monomeric protein
(Figure 3A, lanes 6 and 9).
Discussion
Production of uncoupled glycosylated, quasi-native LASV
GP1 and GP2 proteins was achieved by engineering con-
structs comprised of mammalian cell-specific expression
elements and variants of the GPC complex. The addition
of CMV intron-A was necessary to elicit highly efficient
expression of all GPC variants, reflecting the importance
of this element in the post-transcriptional processing of
the viral messenger RNA. Three SP were successfully used
for expression and translocation of sGP1, including native
GPC SP as well as human IgG λ light-chain and heavy-
chain s.s. The two IgG-derived SP were selected as they are
very efficient secretory signals and fusion of these
domains to heterologous recombinant proteins have been
shown to enhance expression and secretion from mam-
malian cells [15], (Branco, Guttieri, Garry, unpublished
data). Previous studies examining SP substitutions and
GPC expression have not met with similar success. Substi-
tution of the native GPC SP with CD8 α-chain or Influ-
enza virus hemagglutinin (HA) s.s. permitted
translocation of GPC to the ER; however, the protein was
not further proteolytically processed by SKI-1/S1P into
GP1 and GP2 (Eichler et al., 2003). Likewise, Agniho-
thram et al. (2006) demonstrated that the JUNV GPC SP
was required for protein transport to the Golgi and export
to the cell surface. In addition, the cytoplasmic domain of
GP2 encodes a dibasic a.a. motif that is widely utilized in
the retrieval of TM proteins to the ER and that binding of
the SP to this motif masks localization to this organelle,
thereby facilitating the mobilization of the glycoprotein
complex for transit through the Golgi [13]. Although the
GPC SP and IgG-derived s.s. were effective for sGP1
expression, all versions of uncoupled sGP2 containing the
same signal sequences were not effectively processed,
yielding heterogeneously glycosylated species that were
detected only in cell extracts. The relative levels of expres-
sion and pattern of heterogeneous glycosylation were sim-
ilar with each of the s.s. employed, thereby implicating
additional requirements for full post-translational
processing of this protein. Based on these results and pub-
lished observations, the native GPC SP was selected for
the majority of the studies reported here.
PNGase F and Endo H treatment of sGP1-FLAG, GPCΔTMΔIC-FLAG, and GPCΔTM-FLAG from transfected cell supernatants Figure 6
PNGase F and Endo H treatment of sGP1-FLAG, GPCΔTMΔIC-FLAG, and GPCΔTM-FLAG from transfected 
cell supernatants. Twenty μL of each FLAG M2 resin-purified protein from a typical transfection, as shown in figure 3, were 
subjected to treatment with 500 U of PNGase F or Endo H, as described in materials and methods. The reactions were 
resolved on SDS-PAGE gels alongside untreated counterparts, blotted, and probed with anti-FLAG M2 mAb and an HRP-
labeled goat α-mouse IgG. Soluble GP1-FLAG (lanes 1, 2, 3), GPCΔTMΔIC-FLAG (lanes 4, 5, 6), and GPCΔTM-FLAG (lanes 7, 
8, 9) show different mobilities based on whether proteins were treated with PNGase F (lanes 2, 5, 8), Endo H (lanes 3, 6, 9), or 
were left untreated (lanes 1, 4, 7). MagicMark XP™ protein molecular weight markers (M), with sizes (kDa) are shown to the 
left of the panel. Glycosylated species are denoted by (+) CHO, and deglycosylated counterparts by (-) CHO. The addition of 
amydase to each reaction is denoted by (+) symbol below the figure, whereas untreated controls are marked by (-).
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To elucidate the elements critical for sGP2 secretion, vari-
ous GP1- and GP2-expressing constructs were co-
expressed in trans and cis, thereby providing a means to
identify a role, if any, for GP1 as a chaperone or co-factor
in the processing and trafficking of GP2. In addition, the
SKI-1/S1P protease cleavage site was investigated as a pos-
sible determinant for correct processing of GP2, and the
previously identified dibasic amino acid retention signal
in the IC domain of GP2 was evaluated as a modulator of
protein processing and exporting for sGP2 variants.
Co-transfection of vector sGP1 with all three variants of
sGP2 containing only the ectodomain of the protein did
not result in expression and secretion of detectable levels
of GP2. In each instance, similar levels of intracellular
GP2 expression were observed, albeit resulting in hetero-
geneous glycosylation. Higher levels of homogeneously
glycosylated GP1 were observed in extracts from cells co-
transfected with sGP1 and GP2-expressing constructs con-
taining IgG-derived SP. Furthermore, the levels of secreted
GP1 from cells co-transfected with sGP1 and sGP2-hλLC
were consistently lower than with sGP2-hHC, sGP2-GPC
SP, or when compared with sGP1 alone. Although the
mechanisms contributing to these observations were not
determined by these studies, the implications of different
s.s. in the processing efficiency of LASV glycoproteins were
evident. These results clearly demonstrated that expres-
sion of GP1 in trans cannot influence the co-expression,
correct post-translational processing, and secretion of
GP2 from 293T cells.
In contrast, when the ectodomain of GP2 was expressed
with full length GP1 in cis and was driven by the GPC SP,
the resulting sGP2 was very efficiently processed and
secreted from cells (Figure 5B, lanes 3 and 4). Further-
more, the protein was homogeneously glycosylated (Fig-
ure 5B, lanes 3 and 4). Constructs containing a truncated
GP1 that encoded only the C-terminal 10 amino acids of
the ORF, which included the cleavage domain recognized
by SKI-1/S1P protease in addition to the ectodomain of
GP2, did not result in detectable secretion of GP2 protein.
Moreover, the inclusion of the GP2 IC domain did not
influence the correct processing of GP2 unless a full
length GP1 ORF was co-expressed in cis. When only the
GPC SP, Δ59–249, and the GP2 ectodomain were present,
either with or without the IC domain, the resulting intra-
cellular GP2 was consistently heterogeneously glyco-
sylated. However, in repeated studies the presence of a
GP2 IC domain resulted in less heterogeneously glyco-
sylated GP2, further implicating the role of the previously
identified ER retention signal in the correct processing of
the GPC complex. Without cis  expression of GP1, the
inclusion of the GP2 IC resulted only in a semi-homoge-
neously glycosylated GP2 intermediate species that could
not be secreted, providing rationale for involvement of
full length GP1 in the final stage of the export of the SP-
GP1-GP2 complex to the cell surface. Although GPCΔTM-
ΔIC-FLAG and GPCΔTM-FLAG both resulted in the secre-
tion of homogeneously glycosylated sGP2, the inclusion
of the IC domain resulted in higher volumetric protein
production levels, perhaps due to more efficient process-
ing of the chimeric complex via the association of the SP
with the protein and efficient mobilization through the
Golgi. The co-expression of a full length GP1 with GP2 in
cis, driven by the GPC SP and containing the GP2 IC
domain, comprised the shortest module for efficient
processing and secretion of homogeneously glycosylated
GP2.
These studies also revealed that expression of the GPC
complex often results in significant aggregation of glyco-
protein components in the intracellular environment.
Insoluble aggregates greater than 98-kDa, which were not
dispersed by denaturing and reducing agents (e.g., SDS
and DTT), were readily detected. These aggregates were
evident in transfections using the wild type GPC construct
and, more so, using GPCΔ59–249ΔTMΔIC-FLAG and
GPCΔ59–249ΔTM-FLAG. Construct GPCΔTMΔIC-FLAG
generated less aggregate than its Δ59–249 counterpart, with
a pronounced species at ca. 100-kDa that corresponded to
twice the size of an unprocessed molecule. In addition,
less detectable aggregate was generated with GPCΔTM-
FLAG. Furthermore, visible absence of GP2 in extracts
from cells transfected with GPCΔTMΔIC-FLAG and
GPCΔTM-FLAG constructs pointed to very rapid and effi-
cient processing and secretion of sGP2 into the extracellu-
lar environment, in stark contrast to that observed with
Δ59–249  counterparts and, to some extent, sGP1-FLAG.
Whether the apparent sGP2 secretion kinetics played a
role in the formation of less intracellular aggregate is spec-
ulative at this juncture. However, these observations high-
lighted differences in secretion kinetics for individual
LASV glycoproteins. Whereas GP2 can be efficiently and
nearly completed exported from the cell when all co-fac-
tors are present, GP1 displays slower temporal secretory
kinetics, with significant levels of the protein being
detected intracellularly at any given point during the tran-
sient transfection timeline. It can be reasoned that the
newly identified role of co-factor or chaperone for GP1 is
in-line with its slower secretory kinetics, as it would
ensure more efficient processing of GP2, which cannot be
correctly processed and exported on its own. As these
studies point to the crucial role of GP1 expression in cis
with GP2 for efficient processing and secretion of the lat-
ter, both proteins can be readily detected in the extracellu-
lar environment of cells transiently transfected with GPC
variants (Figure 5B, C, lanes 3, 4). Thus, a highly selective
purification process will be required to ensure that prepa-
rations of sGP2 are free of GP1 protein contaminants.Virology Journal 2008, 5:161 http://www.virologyj.com/content/5/1/161
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It has been proposed that GP1 associates non-covalently
with GP2 on the surface of cells [16-18]. This interaction
should be susceptible to disruption by treatment with ani-
onic detergents commonly used in PAGE buffers. How-
ever, our Western blot detection of a prominent high
molecular component purified from the supernatants of
cells transfected with GPCΔTMΔIC-FLAG and GPCΔTM-
FLAG constructs suggested that either sGP1 and sGP2
formed a highly stable heterodimer complex or that
uncleaved GPC polyprotein variants were secreted. If a
heterodimer was generated, it was not disrupted by dena-
turing and reducing conditions, which suggested that a
unique covalent association existed between the two pro-
teins. Alternatively, secreted forms of each unprocessed
polyprotein could have resulted from presence of the SP
and the absence of a TM domain. These polyproteins
appeared fully glycosylated, as their size of ca. 76-kDa cor-
responded to combined sizes of GP1 (ca. 42-kDa) and
GP2 (ca. 36 – 38-kDa) containing a full complement of
carbohydrate. Unglycosylated counterparts migrating in
the 42-kDa range were not detected.
In transient expression experiments, the production pro-
file of wild type GPC and variants should reveal full length
uncleaved complex, as well as fully processed GP1 and
GP2 subunits, with the time of harvest representing a
snapshot of cellular events. Expression of wild type GPC
in 293T/17 cells consistently resulted in the detection of a
ca. 76-kDa species corresponding to GPC, as well as proc-
essed GP1 and GP2 subunits (42-kDa and 38-kDa, respec-
tively). Conversely, GPC gene expression from
GPCΔTMΔIC-FLAG and GPCΔTM-FLAG constructs pri-
marily yielded ca. 68-kDa and 70-kDa species, respec-
tively, in the intracellular protein fraction. Processed,
monomeric GP1 from these constructs was readily
detected with anti-GP1 mAbs (data not shown), but GP2-
FLAG was only detected in the corresponding cell super-
natants. Probing these blots with anti-GP2 mAbs resulted
in the same lack of detection of GP2 as with anti-FLAG M2
reagent, thus confirming the absence of significant levels
of GP2 intracellularly. As outlined above, such observa-
tions point to differential processing and secretion of GP1
and GP2 from both GPC variants, supporting the view
that GP2 was rapidly secreted from the intracellular envi-
ronment and that GP1 was processed via slower secretory
kinetics.
It is also unclear at this juncture whether GPCΔTMΔIC-
FLAG and GPCΔTM-FLAG proteins are specifically but
inefficiently cleaved by SKI-1/S1P protease as a result of
normal virus protein processing or if this phenomenon is
related to the elevated expression levels from the very
strong CMV promoter and associated intron-A sequence
employed in these studies. It is possible that high level
expression of arenaviral GPC overwhelms post-transla-
tional cellular processing mechanisms, thus resulting in a
large fraction of uncleaved protein.
Future studies aimed at finely dissecting the steps
involved in arenaviral GPC processing could benefit from
the use of weaker promoters, such as the basal tyrosine
kinase (TK) elements commonly used to drive expression
of selectable markers in eukaryotic cells [19,20]. Although
the kinetics of GPC processing by SKI-1/S1P protease are
not well understood, a protein concentration-dependent
steady state mechanism could be easily overwhelmed by
the significantly elevated levels of polypeptide synthesis
mediated by CMV promoters in eukaryotic cells. Thus,
these results cannot be used as a correlate for wild type
GPC protein processing efficiency in LASV infected cells.
The strong sGP1-FLAG band detected with anti-GP1 mAb
but not with anti-FLAG mAb in the unbound fraction fol-
lowing capture of the protein with FLAG M2 gel resin
points to the existence of two different variants of this pro-
tein. The sGP1-FLAG used in these studies contained the
native recognition site for SKI-1/S1P protease fused to the
FLAG domain. It is likely that a significant fraction of the
sGP1-FLAG protein was cleaved by SKI-1/S1P protease,
thus generating untagged and FLAG-tagged variants.
Where it concerns the future development of purification
schemes, it may be possible to purify both versions of
sGP1 from the same supernatant pool: sGP1-FLAG can be
captured by FLAG-M2 resin and the flow through, con-
taining untagged protein, could subsequently be purified
by LASV GP1 affinity chromatography. Alternatively,
mutating the SKI-1/S1P protease recognition domain
from RRLL to RRAA would abrogate cleavage of the down-
stream purification tag and thus increase yields of recom-
binant protein via a single chromatography step (Dr. Erica
Ollmann Saphire, Kathryn Weinell, The Scripps Research
Institute, La Jolla, CA, personal communication).
These studies established that expression of wild type GPC
in human cells results in the generation of a significant
sGP1 fraction, reflecting either the functional role the pro-
tein serves in the infection process (e.g., binding to host
cell glycans) or to a weak interaction between GP1 and
GP2 on the cell surface that readily leads to dissociation of
this complex. In our studies, sGP1 expressed from a wild
type GPC molecule consistently yielded largely mono-
meric protein in the extracellular environment of trans-
fected cells. In contrast, secreted GP1 from sGP1-FLAG
consistently resulted in the generation of dimer and
trimer species. As analysis of sGP1 protein in these studies
was performed under denaturing and reducing condi-
tions, homodimer and homotrimer species may have rep-
resented covalently associated subunits. A likely
explanation for the presence of significant levels of sGP1
in the supernatants of cells transfected with wild type GPCVirology Journal 2008, 5:161 http://www.virologyj.com/content/5/1/161
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is glycoprotein ectodomain shedding. This phenomenon
has been widely reported and characterized in Ebola virus
(EBOV) glycoprotein expression, which has similar fea-
tures to that of LASV and other arenaviral GPCs [21-25].
Dolnik et al. (2004) reported that the abundant release of
EBOV surface glycoprotein GP in a soluble form from
virus-infected cells was mediated by cellular shedases.
These studies also showed that tumor necrosis factor α-
converting enzyme (TACE), a member of the ADAM fam-
ily of zinc-dependent metalloproteinases, is involved in
EBOV GP shedding from virus infected cells. Evidence of
significant amounts of shed GP in the blood of EBOV-
infected animals was obtained in these studies, and a cor-
relation was established between high levels of the sGP
and pathogenesis via efficient blocking of the activity of
virus-neutralizing circulating antibodies. Preliminary
studies in our laboratory indicate that, unlike with EBOV
GP, ectodomain shedding mediated by shedases (zinc-
dependent mettaloproteinases) is not a mechanism by
which LASV sGP1 is secreted into the extracellular envi-
ronment of GPC-expressing mammalian cells (unpub-
lished observations). The current proposed model for
arenaviral glycoprotein complex structure is comprised of
membrane-anchored GP2 homotrimers with non-cova-
lently associated GP1 homotrimers [17]. Thus, it is more
likely that secreted GP1 represents an intracellularly
cleaved and processed protein fraction that does not asso-
ciate with GP2 and SP. Nevertheless, the similarity
between EBOV and LASV secreted glycoprotein compo-
nents establishes a possible mechanistic and pathogenic
correlate among hemorrhagic fever viruses. It is well estab-
lished that proteolytic cleavage of GPC processing in are-
naviruses is the mechanism by which GP1 and GP2 are
generated in virus-infected cells. To date, it has not been
shown that arenaviral pre-GPC messenger RNA undergoes
alternate splicing to generate a soluble form of GP1. Thus,
extracellular arenaviral GP1 is likely to emerge as a result
of secretion of this protein throughout the assembly and
maturation stages of the membrane-anchored glycopro-
tein complex during viral biogenesis. The implications for
secreted GP1 in viral pathogenesis in humans is not
known at this time, but further studies will be aimed at
establishing possible correlates, particularly as they relate
to early diagnosis of hemorrhagic fevers.
The glycosylation pattern present in sGP1 and sGP2 vari-
ants was analyzed by treating purified proteins with the
amidases PNGase F and Endo H. Treatment with both
amidases resulted in the reduction of the molecular
weights of sGP1 and sGP2. These data confirmed that
both protein species were glycosylated and that high man-
nose glycans accounted for this modification. Many glyc-
osylated proteins generated in mammalian cells contain
high mannose glycan side groups, and their role in correct
protein folding, function and stability have been well doc-
umented [26,27]. Although it has been recently reported
by Branco et al.,2008 [28] that LASV GP1 and GP2 can be
successfully expressed and purified as full length proteins
from Escherichia coli (E. coli), both lack post-translational
modifications, namely glycosylation. The bacterially
expressed proteins were readily recognized by mAbs
raised against native viral antigen preparations, as well as
by antibodies in LASV convalescent human sera. These
results should not, however, preclude the expression,
purification, and utilization of quasi-native glycoproteins
in the development of highly sensitive diagnostic assays.
It is likely that antibodies raised against conformational
and modified epitopes could represent an important frac-
tion of the Ig component in infected and convalescent
patients. Modern mammalian cell line-based expression
platforms have significantly reduced the costs associated
with generation of recombinant proteins on a volumetric
basis. Several highly efficient platforms exist that permit
the generation of tens to a few hundred milligrams of
recombinant protein per liter of culture in less than one
week (Freestyle 293F Expression System, CHO-S and
CHO DG44 cells and media kit e.g., Invitrogen). High
expression levels of quasi-native proteins coupled to rapid
and efficient affinity chromatography-based purification
methods make a mammalian expression platform com-
petitive in the generation of important diagnostic proteins
with extended functional properties.
Conclusion
The work reported here provides a basis for developing
reagents that could be used in diagnostic platforms and
applied to studies aimed at developing countermeasures
to thwart Lassa fever. Furthermore, the mechanisms of
arenaviral glycoprotein gene expression elucidated in this
report establish a means by which to investigate poten-
tially highly relevant aspects of early diagnosis and disease
progression in hemorrhagic fevers.
Methods
Cell culture, LASV propagation, RNA preparation, cDNA 
synthesis
HEK-293T/17 cells (ATCC CRL11268) were maintained
in complete high glucose Dulbecco's Modified Eagle
Medium (cDMEM) supplemented with non-essential
amino acids (NEAA) and 10% heat-inactivated fetal
bovine serum (ΔFBS).
Vero cells (ATCC CRL 1587) were maintained in complete
Eagle's Minimal Essential Medium (cEMEM) supple-
mented with NEAA, 10% ΔFBS, and 20 μg/mL gen-
tamicin. Vero cells were infected with LASV strain Josiah,
[29] at a multiplicity of infection of 0.1. Briefly, virus was
diluted in cEMEM to a final volume of 2.0 mL, then added
to confluent cells in a T-75 flask and incubated for 1 hour
(h) at 37°C, 5% CO2 with periodic rocking. Subsequently,Virology Journal 2008, 5:161 http://www.virologyj.com/content/5/1/161
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13 mL of cEMEM was added, and the culture was incu-
bated in a similar manner for 96 h. To prepare total cellu-
lar RNA, the cell culture medium was replaced with 2 mL
of TRIzol reagent (Invitrogen, Carlsbad, CA), and total
RNA was purified according to the manufacturer's specifi-
cations. Total cellular RNA was reverse transcribed with
the ProtoScript First Strand cDNA Synthesis Kit (New Eng-
land Biolabs, Ipswich, MA), as outlined in the manufac-
turer's protocol. All LASV gene sequence variants were
amplified from cDNA using Phusion™ High-Fidelity
polymerase chain reaction (PCR) Mastermix (New Eng-
land Biolabs).
Construction of plasmids for protein expression
For LASV protein expression in mammalian cells,
pcDNA3.1(+) (Invitrogen) was used as the plasmid vector
backbone for all constructs. The vector was modified to
contain the entire 1.5-kbp CMV-MIE intron-A (intA)
sequence immediately downstream of the parental plas-
mid's CMV promoter, and was designated
pcDNA3.1(+):intA. All LASV gene variants were sub-
cloned as blunt-ended PCR products into the intermedi-
ary vector pCR-Blunt II-TOPO®  (Invitrogen) and were
subsequently cloned via the NheI and HindIII restriction
sites within the multiple cloning site of
pcDNA3.1(+):intA. The cloning strategy for all variants of
LASV GPC, GP1, and GP2 gene sequences into the mam-
malian expression vector is outlined in Figure 1. DNA was
manipulated by standard techniques [30], and all recom-
binant plasmids were engineered and propagated in
Escherichia coli (E. coli) strain DH5α, according to the
manufacturer's instructions (Invitrogen). The DNA
sequence and rationale for all oligonucleotides employed
in the generation of expression constructs are outlined in
Table 1 and in Additional file 1. The accuracy of all LASV
GPC, GP1, and GP2 constructs was confirmed by double
stranded DNA sequencing (Macrogen, Rockville MD).
Transient expression of LASV gene constructs
Recombinant LASV protein expression was analyzed in
HEK-293T/17 cells transiently transfected with mamma-
lian expression vector DNAs, which were prepared using
the PureLink HiPure plasmid filter midiprep kit (Invitro-
gen). The negative control vector pcDNA3.1(+):intA was
included in all transfections. Briefly, 1 × 106 cells were
seeded per well of a Poly-D-Lysine-coated 6-well plate in
2 mL of cDMEM. After overnight incubation at 37°C, 5%
CO2, 90% relative humidity (RH) cells were transfected
with unrestricted recombinant plasmid DNAs using the
cationic lipid reagent Lipofectamine™ 2000 (Invitrogen),
according to the manufacturer's instructions. Four μg of
each plasmid DNA were used per transfection. In co-trans-
fection experiments a total of 8 μg were used per reaction
(e.g. 4 μg sGP1 and 4 μg sGP2-hHC). Transfections were
incubated for 72 h at 37°C, 5% CO2, 90% RH after which
cell culture supernatants were collected and clarified by
centrifugation. To prepare cell extracts from transfected
cultures, cell monolayers were carefully washed twice with
Ca++- and Mg++-free PBS, pH7.4, collected by gentle dis-
lodging, transferred to 1.5 mL polypropylene tubes, and
lysed for 10 minutes in a mammalian cell lysis buffer
comprised of 50 mM Tris buffer, pH 7.5, 1 mM EDTA,
0.1% SDS, 0.5% deoxycholic acid, 1% Igepal CA-360, and
a protease inhibitor cocktail (Sigma Aldrich, St. Louis,
MO), according to the manufacturer's instructions. The
insoluble fraction was pelleted by centrifugation at
14,000 × g for 10 minutes, and the supernatants were
transferred to fresh tubes. Protein concentration was
determined for each sample with a Bradford assay kit, as
indicated by the manufacturer (Pierce, Rockford, IL).
Western blot analysis of recombinant LASV proteins
Expression of LASV proteins in mammalian cells was con-
firmed by Western blot analysis using anti-LASV GP1 or
GP2 specific mAbs, or M2-FLAG mAb (Sigma Aldrich).
Briefly, 10 μg of total cell protein in 10 μL (~1 × 105 cell
equivalents) or 20 μL of cell culture supernatant were
resolved by SDS-PAGE in 10% NuPAGE Novex Bis-Tris
gels, according to the manufacturer's specifications
(Novex, San Diego, CA). All samples in these studies were
denatured and reduced in SDS-PAGE buffer containing
DTT. Proteins were transferred to 0.45-μm nitrocellulose
membranes using XCell II™ Blot Modules, according to
the manufacturer's instructions (Invitrogen). Blocking
and probing of membranes were performed in 1× PBS, pH
7.4, 5% non-fat dry milk, 0.05% Tween-20, and 0.1%
thymerosal. Membranes were washed with 1× PBS, pH
7.4, 0.1% Tween-20 (wash buffer), then probed for 1 hour
at room temperature in 10–15 mL of blocking buffer con-
taining 1 μg/mL of relevant murine mAb, washed and
incubated for an additional hour with Horseradish perox-
idase (HRP)-conjugated goat anti-mouse IgG (H+L) anti-
body reagent in blocking buffer. Membranes were then
washed extensively and developed with TMB membrane
substrate purchased from Kirkegaard and Perry Laborato-
ries (KPL, Gaithersburg, MD). Reactions were stopped by
immersing developed membranes in water, followed by
immediate high resolution scanning for permanent
recording.
PNGase F and Endo H assays
The glycosylation patterns in recombinantly expressed
sGP1 and sGP2 were resolved by treatment with the gly-
cosidases PNGase F and Endo H. Twenty μL of FLAG M2
resin-purified proteins from supernatants of HEK-293T/
17 cells transiently transfected with sGP1-FLAG,
GPCΔTM-FLAG, or GPCΔTMΔIC-FLAG were subjected to
treatment with 500 U of PNGase F or Endo H for 1 hourVirology Journal 2008, 5:161 http://www.virologyj.com/content/5/1/161
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Table 1: Oligonucleotide primers used for amplification of LASV genes expressed in mammalian cells (see Additional file 1)
LASV gene amplified LASV primer Oligonucleotide primer sequence
GPC 5' GPC GTAGCTAGCATGGGACAAATAGTGACATTCTTCCAG
3' GPC GGTACCAAGCTTTCAGTCATCTCTTCCATTTCACAGGCAC
GPC-FLAG 5' GPC
3' GPC-FLAG CGATAAGCTTTCAGTCAGCCCTTGTCGTCGTCGTCCTTGTAGT
CTCTCTTCCATTTCACAGGCAC
sGP1 5' GPC
3' sGP1 GGTACCAAGCTTTCAGTCATAGCAATCTTCTACTAATATAAATATCTCT
sGP1-FLAG 5' GPC
3' sGP1-FLAG CGATAAGCTTTCAGTCAGCCCTTGTCGTCGTCGTCCTTGTAGTCT
AGCAATCTTCTACTAATATA
sGP1-hHC 5' hHC-sGP1 GATCGCTAGCGCCGCCACCATGGGCTGGAGCTGCATCATCCTGTTCCTGGTGG
CCACCGCCACCGGCGTGCACAGCACCAGTCTTTATAAAGGGGTT
3' sGP1
sGP1-hλLC 5' hλLC-sGP1 AAGCTGGCTAGCCACCATGGCCTGGTCTCCTCTCCTCCTCACTCTCCTCGCTC
ACTGCACAGGGTCCTGGGCCCAGACCAGTCTTTATAAAGGGGTT
3' sGP1
GP1-TM 5' GPC
3' GP1-TM GGTACCAAGCTTTCAGTCATGGTATTTTGACTAGGTGAAGGAAGATGCTAATAAGATAGAAACTTG
TGCTGAACACAAAGAGGTCAACTAGACCCAATGGTAGCAATCTTCTACTAATATAAATATCTCT
sGP2-GPC SP 5' GPC
sGP2-GPC SP CAGTGTCCATGTGAATGTGCCGGTTGTGCAAGACCATCCACACAA
5' GPC
3' GP2preTM GGTACCAAGCTTTCAGCTATGTCTTCCCCTGCCTCTCCAT
sGP2-hHC 5' hHC-sGP2 GATCGCTAGCGCCGCCACCATGGGCTGGAGCTGCATCATCCTGTTCCTGGTGG
CCACCGCCACCGGCGTGCACAGCGGCACATTCACATGGACACTG
3' sGP2preTM
sGP2-hHC-TM 5' hHC-sGP2
3' GP2-TM GGTACCAAGCTTTCAGTCATGGTATTTTGACTAGGTGAAGGAA
sGP2-hHC-FLAG 5' hHC-sGP2
3' GP2preTM-
FLAG
CGATAAGCTTTCAGTCAGCCCTTGTCGTCGTCGTCCTTGTAGT
CTGTCTTCCCCTGCCTCTCCAT
GP2-hHC-TM-FLAG 5' hHC-sGP2
3' GP2-TM-FLAG CGATAAGCTTTCAGTCAGCCCTTGTCGTCGTCGTCCTTGTAGTCTGGT
ATTTTGACTAGGTGAAGGAA
s GP2-hλLC 5' hλLC-sGP2 AAGCTGGCTAGCCACCATGGCCTGGTCTCCTCTCCTCCTCACTCTCCTCGCTC
ACTGCACAGGGTCCTGGGCCCAGGGCACATTCACATGGACACTG
3' sGP2preTM
sGP2-hλLC-TM 5' hλLC-sGP2Virology Journal 2008, 5:161 http://www.virologyj.com/content/5/1/161
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using the reaction conditions suggested by the manufac-
turer (New England Biolabs). Control reactions were sim-
ilarly processed except that enzymes were not added.
Following incubation proteins were resolved by reducing
SDS-PAGE, blotted, probed with anti-FLAG M2 mAb and
secondary reagent, and developed as described above.
Purification of FLAG-tagged sGP1 and sGP2 from culture 
supernatants
To purify sGP1-FLAG and sGP2-FLAG proteins, 1 mL of
supernatant harvested from 293T/17 cells transiently
transfected with construct sGP1-FLAG, GPCΔTM-FLAG, or
GPCΔTMΔIC-FLAG was clarified by brief centrifugation at
14,000 × g and subjected to ANTI-FLAG M2 affinity gel
(Sigma Aldrich)-based immunoprecipitation (IP). Briefly,
1 mL of cleared supernatant was added to 40 μL of washed
resin and agitated in a roller shaker for 2 hours at room
temperature. The gel was then pelleted by brief centrifuga-
tion at 6,000 × g and the supernatant was transferred to a
fresh tube. This supernatant was used to analyze the
unbound fraction of FLAG-tagged protein. The gel was
washed three times with wash buffer (50 mM Tris HCl, pH
7.4, 150 mM NaCl), followed by resuspension in 100 μL
of wash buffer containing 150 ng/mL of 3× FLAG peptide
3' GP2-TM
GPCΔTMΔIC 5' GPC
3' GP2preTM
GPCΔTMΔIC-FLAG 5' GPC
3' GP2preTM-
FLAG
CGATAAGCTTTCAGTCAGCCCTTGTCGTCGTCGTCCTTGTAGTCTGT
CTTCCCCTGCCTCTCCAT
GPCΔTM-FLAG 5' GP2 TM 
deletion
AAAATACCAACTCATAGGCATATTGTAG
3' TM deletion GGAGTATATGGAGAGGCAGGGGAAGACA
GPCΔ59–249ΔTMΔIC 5'GPC
3' SKI-1/GP2 CAGTGTCCATGTGAATGTGCCTAGCAATCTTCTACTAATATAAATATCTCTGGTT
GTGCAAGACCTACCACACAA
5' GPC
3' GP2preTM
GPCΔ59–249ΔTMΔIC-FLAG 5'GPC
3' SKI-1/GP2
5' GPC
3' GP2preTM-
FLAG
GPCΔ59–249ΔTM 5' GPC
3' SKI-1/GP2
5' GPC
3' GPC-FLAG
Table 1: Oligonucleotide primers used for amplification of LASV genes expressed in mammalian cells (see Additional file 1) (Continued)Virology Journal 2008, 5:161 http://www.virologyj.com/content/5/1/161
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Hypothetical arenaviral glycoprotein expression pathway and secretory forms Figure 7
Hypothetical arenaviral glycoprotein expression pathway and secretory forms. Arenaviral glycoprotein (GP) 
mRNA is transcribed from plasmid DNA constructs in the host cell (1), and directed to the rough endoplasmic reticulum 
(RER) for translation. The nascent polyprotein is directed to the RER lumen by the SP, where SPases cleave SP from the GP 
polyprotein precursor (2). In the RER the GP precursor is cleaved by SKI-1/S1P to yield GP1 and GP2 (3). Wild-type GP may 
be comprised of covalently-linked GP1 and GP2, and associated SP (3a). In GPCΔTM (3b) and GPCΔTMΔIC (3c) truncated 
GP2 subunits may associate covalently with GP1. The role of SP in these variants is unknown. A GP fraction expressed from 
constructs GPCΔTM and GPCΔTMΔIC that is not processed by SKI-1/S1P could shuttle uncleaved polyprotein to the glyco-
sylation pathway (3d). The SP’s role here is also unknown. Glycosylation of GP1 and GP2 is mediated by RER or Golgi glycosyl-
transferases (4). Membrane-bound vesicles transport proteins to the Golgi cis face where processing and assembly occur. 
Assembled and glycosylated GP complex or subunits are packaged in exocytic vesicles that emerge from the Golgi trans face 
and are directed toward the plasma membrane (5). The GP complex is anchored via the GP2 transmembrane domain (6a, b). 
Complexed heterodimeric GP1–GP2 is displayed in 6a, whereas GP spike trimer in a hypothetical prefusion form is shown in 
6b. Extracellular GP1 from expression of wild-type GPC may be produced by protease-mediated ectodomain shedding, or an 
isoform of secreted GP1. The potential forms of the GP complex and subunits are outlined in 7. Monomeric sGP1 and 
homodimer (7a), soluble monomeric GP2 and GP1, complexed heterodimer, or the potentially uncleaved GP precursor (in 
etched box) derived from GPCΔTM (7b) and GPCΔTMΔIC (7c) are shown. Legend box: Graphic representations of relevant 
components.
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(elution buffer). The samples were incubated with agita-
tion in a roller shaker for 30 minutes at 4°C to elute
bound proteins. The gel was subsequently centrifuged at
6,000 × g for 30 seconds, and the supernatants containing
the eluted protein were transferred to a fresh tube. Twenty
μL of each supernatant were subjected to reducing SDS-
PAGE and western blot analyses, as described above.
Monoclonal antibodies to LASV proteins
For immunoassays, Dr. Randy Schoepp (Diagnostic Sys-
tems Division, USAMRIID, Ft. Detrick, MD) kindly pro-
vided the following LASV-specific monoclonal antibodies
(mAbs): GP1-specific mAb L52-74-7A IgG1; GP2-specific
mAbs L52-272-7 IgG1 and L52-121-22 IgG2a. These
mAbs were raised against purified gamma-irradiated
LASV, as previously described [31].
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